RxDoctor Payments Data

Noel Rosado Adames, MD

Ophthalmology · Arecibo, PRNPI 1922295930

Payments from drug & device makers

$1,092in general payments, 2019–2025

Across 27 payments — averaging $40.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$195
  • Alcon$169
  • Bausch & Lomb Americas Inc.$166
  • AbbVie$157
  • Alcon Puerto Rico Inc$99
  • Carl Zeiss Meditec USA, Inc.$69
  • plus $236 from 10 others

What the payments were for

  • Food & beverage$1,092100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,092 in reported general payments places this provider in the 60th percentile of 214 ophthalmology providers in Puerto Rico.

See all ophthalmology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$14,387
Medicare patients
29
Services billed
122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine111$73,134
LumiganBimatoprost161$43,057
Prednisolone Acetate1,098$42,129
Cyclosporine123$26,062
Fluorometholone279$18,460
XiidraLifitegrast21$15,710
Ofloxacin714$14,581
Tobramycin-DexamethasoneTobramycin/Dexamethasone230$11,671
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol71$8,676
Latanoprost682$7,523
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat221$7,125
Alphagan PBrimonidine Tartrate28$5,456
Brimonidine Tartrate114$4,734
Timolol Maleate288$2,960
Difluprednate18$2,501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$157$121,647300 claims
Bausch & Lomb Americas Inc.Xiidra$166$15,71021 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$13$1,66811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 214 ophthalmology providers in Puerto Rico.

Other ophthalmology in Arecibo

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →